Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin degludec/liraglutide versus basal insulin analogues for remission in early type 2 diabetes
ChiCTR2500101696Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Guangxi University of Chinese Medicine
- Start
- Apr 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of insulin degludec, liraglutide, insulin glargine and insulin detemir in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by First Affiliated Hospital of Guangxi University of Chinese Medicine. Primary endpoints: Glycosylated hemoglobin and Urinary microalbumin/creatinine. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500101696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101696.